NCT06591091View on ClinicalTrials.gov

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Depression
Interventions
DRUG

Clemastine Fumarate

Listed in arm/group description

DRUG

Placebo

Listed in arm/group description

All Listed Sponsors
collaborator

Cures Within Reach

OTHER

lead

University of Illinois at Chicago

OTHER

NCT06591091 - Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression | Biotech Hunter | Biotech Hunter